TY - JOUR T1 - Prevalence evolution of SARS-CoV-2 infection in the Municipality of São Paulo, 2020 - 2021 JF - medRxiv DO - 10.1101/2021.06.16.21256530 SP - 2021.06.16.21256530 AU - Jose O M Albuquerque AU - Gabriela A Kamioka AU - Geraldine Madalosso AU - Selma A Costa AU - Paula B Ferreira AU - Francisco A Pino AU - Ana Paula S Sato AU - Ana Carolina A Carvalho AU - Ana Beatriz P Amorim AU - Caroline C Aires AU - Ana Paula A G Kataoka AU - Elisa S M M Savani AU - Thirsa A F Bessa AU - Breno S Aguiar AU - Marcelo A Failla AU - Edson A Santos AU - Edjane M T Brito AU - Maria C H Santos AU - Solange M S Silva AU - Luiz A V Caldeira AU - Luiz C Zamarco AU - Sandra M S Fonseca AU - Marcia M C Lima AU - Ivanilda A Marques AU - Fabiana E V Silva AU - Paula R Glasser AU - Patrícia C P R Burihan AU - Cinthya L Cavazzana AU - Renata C Lara AU - Debora S Mello AU - Alessandra C G Pellini AU - Fernando Y Nishio AU - Fernanda M Kian AU - Elza S Braga AU - Nilza M P Bertelli AU - Wagner Fracini AU - Marcelo D A Gonçalves AU - Paulete S Zular AU - Regiane S Piva AU - Eduardo de Masi Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/20/2021.06.16.21256530.abstract N2 - Objectives To estimate the evolution of the prevalence of SARS-CoV-2 virus infection among residents aged 18 years or over in the municipality of São Paulo.Methods This is a population-based household survey conducted every 15 days, between June and September 2020 and January and February 2021. In total, 11 phases were performed. The presence of antibodies against SARS-CoV-2 was identified in venous blood using a lateral flow test, Wondfo Biotech. In the last phase, it was combined with an immunoenzymatic test, Euroimmun. Participants also answered a semi-structured questionnaire on sociodemographic and economic factors and social distancing measures. Prevalence estimates and 95% confidence intervals were estimated according to the region, Human Development Index, sex, age group, ethnicity, education, income and variables associated with risk or prevention of the infection. To compare the frequencies among the categories of each variable, the chi-square test with Rao Scott correction was used, considering a 5% significance level.Results In total, 23,397 individuals were interviewed and had their samples collected. The estimated prevalence of antibodies against SARS-CoV-2 ranged from 9.7% (95%CI: 7.9-11.8%) to 25.0% (95%CI: 21.7-28.7). The prevalence of individuals with antibodies against SARS-CoV-2 was higher among black and pardo people, people with lower schooling, people with lower income and among residents of regions with lower Human Development Index. The lowest prevalences were associated with recommended measures of disease protection. The proportion of asymptomatic infection was 45.1%.Conclusion The estimated prevalence of SARS-CoV-2 infection was lower than the cumulative incidence variation, except for the last phase of the study. The differences in prevalence estimates observed among subpopulations showed the social inequality as a risk of infection. The lower prevalence observed among those who could follow prevention measures reinforce the need to maintain the social distancing measures as ways to prevent SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by Brazilian's National Ethics Commitee (CAAE 32947920.3.0000.0008).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, SMS/COVISA. The data are not publicly available due to restrictions of their containing information that could compromise the privacy of research participants. ER -